292 related articles for article (PubMed ID: 15056042)
1. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
3. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
Leitch HA; Connors JM
Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
[TBL] [Abstract][Full Text] [Related]
4. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
[TBL] [Abstract][Full Text] [Related]
5. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
Bendandi M
Expert Rev Anticancer Ther; 2001 Jun; 1(1):65-72. PubMed ID: 12113135
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
Timmerman JM
Adv Pharmacol; 2004; 51():271-93. PubMed ID: 15464914
[No Abstract] [Full Text] [Related]
9. Vaccines for lymphomas: idiotype vaccines and beyond.
Houot R; Levy R
Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
[TBL] [Abstract][Full Text] [Related]
10. [Past, present and future of anti-idiotype vaccination].
Rodríguez Calvillo M; Inogés S; López Díaz de Cerio A; Zabalegui N; Panizo C; Hernández M; Pérez Calvo J; Prósper F; Melero I; Sánchez-Ibarrola A; Rocha E; Bendandi M
Rev Med Univ Navarra; 2004; 48(3):14-23. PubMed ID: 15622921
[TBL] [Abstract][Full Text] [Related]
11. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
Reinis M
Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
[TBL] [Abstract][Full Text] [Related]
12. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.
Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Zabalegui N; Villanueva H; Bendandi M
Crit Rev Oncol Hematol; 2004 Oct; 52(1):1-7. PubMed ID: 15363462
[TBL] [Abstract][Full Text] [Related]
13. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic clonotypic vaccines.
Schwartz RS
N Engl J Med; 1992 Oct; 327(17):1236-7. PubMed ID: 1406797
[No Abstract] [Full Text] [Related]
15. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
[TBL] [Abstract][Full Text] [Related]
20. Idiotype vaccines for human B-cell malignancies.
Inoges S; de Cerio AL; Soria E; Villanueva H; Pastor F; Bendandi M
Curr Pharm Des; 2010 Jan; 16(3):300-7. PubMed ID: 20109139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]